REFERENCES
- Almirante B, Rodriguez D, Park BJ, Cuenca-Estrella M, Pla-nes AM, Almela M, et al. Barcelona Candidemia Project Study Group. Epidemiology and predictors of mortality in cases of Can-dida bloodstream infection: results from population-based sur-veillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829–1835.
- Falagas ME, Ntziora F, Betsi GI, Samonis G. Caspofungin for the treatment of fungal infections: a systematic review of ran-domized controlled trials. Int J Antimicrob Agents 2007; 29: 136–143.
- Chryssanthou E, Cuenca-Estrella M. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed stan-dard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol 2002 ; 40: 3841–3844.
- Ellis D. Amphotericin B: spectrum and resistance. J An-timicrob Chemother 2002; 49: 7–10.
- Barchiesi F, Maracci M, Baldassarri I, Spreghini E, Giannini D, Scalise G. Tolerance to amphotericin B in clinical isolates of Candida tropicalis. Diagn Microbiol Infect Dis 2004; 50: 179–185.
- Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006; 57: 705–708.
- Canton E, Peman J, Gobernado M, Viudes A, Espinel-In-groff A. Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob Agents Chemother 2004; 48: 2477–2482.
- Moudgal V, Little T, Boikov D, Vazquez JA. Multi-echinocandin- and multiazole-resistant Candida parapsilosis iso-lates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005; 49: 767–769.
- Justerreicher A, Flidel-Rimon O, Amitay M, Even-Toy S, Shinwell E, Leibovitz E. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Eur J Clin Mi-crobiol Infect Dis 2003; 22: 603–607.
- Lequaglie C. Liposomal amphotericin B (AmBisome): efficacy and safety of low-dose therapy in pulmonary fungal infections. J Antimicrob Chemother 2002; 49: 49–50.
- Nguyen TH, Hoppe-Tichy T, Geiss HK, Rastall AC, Swo-boda S, Schmidt J, et al. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J An-timicrob Chemothe 2007; 60: 100–106.
- Chou LS, Lewis RE, Ippoliti C, Champlin RE, Kontoyian-nis DP. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy 2007; 27: 1644–1650.
- Carrillo-Mutioz AJ, Quindós G, del Valle O, Santos P, Giu-siano G, Ezkurra PA, et al. Activity of caspofungin and voricona-zole against clinical isolates of Candida and other medically important yeasts by the CLSI M-44A disk diffusion method with Neo-Sensitabs tablets. Chemotherapy 2008; 54: 38–42.
- Pasqualotto AC, Denning DW. New and emerging treat-ments for fungal infections. J Antimicrob Chemother 2008; 61: 19–30.
- Wiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE. Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother 2005; 49: 5146–5148.